TY - JOUR
T1 - Melatonin as an adjuvant treatment modality with doxorubicin
AU - Maleki Dana, Parisa
AU - Sadoughi, Fatemeh
AU - Reiter, Russel J.
AU - Mohammadi, Sotoudeh
AU - Heidar, Zahra
AU - Mirzamoradi, Masoumeh
AU - Asemi, Zatollah
N1 - Publisher Copyright:
Copyright © 2022 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Combination chemotherapy seems to be a beneficial choice for some cancer patients particularly when the drugs target different processes of oncogenesis; patients treated with combination therapies sometimes have a better prognosis than those treated with single drug chemotherapy. However, research has shown that this is not always the case, and this approach may only increase toxicity without having a significant effect in augmenting the antitumor actions of the drugs. Doxorubicin (Dox) is one of the most common chemotherapy drugs used to treat many types of cancer, but it also has serious side effects, such as cardiotoxicity, skin necrosis, testicular toxicity, and nephrotoxicity. Many studies have examined the efficiency of melatonin (MLT) as an anticancer agent. In fact, MLT is an anti-cancer agent that has various functions in inhibiting cancer cell proliferation, inducing apoptosis, and suppressing metastasis. Herein, we provide a comprehensive evaluation of the literature concerned with the role of MLT as an adjuvant in Dox-based chemotherapies and discuss how MLT may enhance the antitumor effects of Dox (e.g., by inducing apoptosis and suppressing metastasis) while rescuring other organs from its adverse effects, such as cardio- and nephrotoxicity.
AB - Combination chemotherapy seems to be a beneficial choice for some cancer patients particularly when the drugs target different processes of oncogenesis; patients treated with combination therapies sometimes have a better prognosis than those treated with single drug chemotherapy. However, research has shown that this is not always the case, and this approach may only increase toxicity without having a significant effect in augmenting the antitumor actions of the drugs. Doxorubicin (Dox) is one of the most common chemotherapy drugs used to treat many types of cancer, but it also has serious side effects, such as cardiotoxicity, skin necrosis, testicular toxicity, and nephrotoxicity. Many studies have examined the efficiency of melatonin (MLT) as an anticancer agent. In fact, MLT is an anti-cancer agent that has various functions in inhibiting cancer cell proliferation, inducing apoptosis, and suppressing metastasis. Herein, we provide a comprehensive evaluation of the literature concerned with the role of MLT as an adjuvant in Dox-based chemotherapies and discuss how MLT may enhance the antitumor effects of Dox (e.g., by inducing apoptosis and suppressing metastasis) while rescuring other organs from its adverse effects, such as cardio- and nephrotoxicity.
KW - Chemotherapy
KW - Doxorubicin
KW - Melatonin
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85142403721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142403721&partnerID=8YFLogxK
U2 - 10.1016/j.biochi.2022.06.007
DO - 10.1016/j.biochi.2022.06.007
M3 - Article
C2 - 35752222
AN - SCOPUS:85142403721
SN - 0300-9084
VL - 202
SP - 49
EP - 55
JO - Biochimie
JF - Biochimie
ER -